Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the technology is an option alongside current standard treatment options.
The list price of tofacitinib has a discount that is commercial in confidence. For enquiries about the patient access scheme contact Jo.Wallis@pfizer.com.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: 11 October 2017